心血管生物标志物：过去的经验教训与未来展望。
Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future.
机构信息
Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.
出版信息
Int J Mol Sci. 2022 May 19;23(10):5680. doi: 10.3390/ijms23105680.
Cardiovascular diseases (CVDs) are a major healthcare burden on the population worldwide. Early detection of this disease is important in prevention and treatment to minimise morbidity and mortality. Biomarkers are a critical tool to either diagnose, screen, or provide prognostic information for pathological conditions. This review discusses the historical cardiac biomarkers used to detect these conditions, discussing their application and their limitations. Identification of new biomarkers have since replaced these and are now in use in routine clinical practice, but still do not detect all disease. Future cardiac biomarkers are showing promise in early studies, but further studies are required to show their value in improving detection of CVD above the current biomarkers. Additionally, the analytical platforms that would allow them to be adopted in healthcare are yet to be established. There is also the need to identify whether these biomarkers can be used for diagnostic, prognostic, or screening purposes, which will impact their implementation in routine clinical practice.
心血管疾病（CVDs）是全球人口的主要医疗负担。早期发现这种疾病对于预防和治疗至关重要，可以最大限度地减少发病率和死亡率。生物标志物是诊断、筛查或提供病理状况预后信息的重要工具。本综述讨论了用于检测这些疾病的历史心脏生物标志物，讨论了它们的应用和局限性。自那时以来，新的生物标志物已取代了这些标志物，现在已在常规临床实践中使用，但仍无法检测到所有疾病。未来的心脏生物标志物在早期研究中显示出前景，但仍需要进一步的研究来证明它们在提高 CVD 检测方面优于当前的生物标志物。此外，还需要建立允许它们在医疗保健中使用的分析平台。还需要确定这些生物标志物是否可用于诊断、预后或筛查目的，这将影响它们在常规临床实践中的实施。
Zotero 插件